Current Signal Transduction Therapy

Dr. Cardoso is a Professor of Biochemistry and Immunology of the Medicine Course at Federal University of Fronteira Sul (Brazil). For over 10 years, her research group has a long-standing interest in the mechanisms related to the involvement of purinergic signaling and oxidative injury in various diseases, especially on many types of cancer, sepsis, as well as others non communicable diseases such as hypertension. The focus of her research has been the physiopathology mechanisms and the role of ectonucleotidases and ATP on disease development. Dr. Cardoso has authored more than 30 pubmed-indexed manuscripts.

Prof. Junfeng Su is a doctoral tutor and fellow of the International Water Association (IWA). Currently, he is a Professor at the School of Environmental and Municipal Engineering, Xi’an University of Architecture and Technology of China. The current research interests of his group include (1) Wastewaters and groundwater biotreatment by biofilm (2) Genomics, transcriptomics and proteomics of autotrophic denitrifying bacteria and metal oxidizing bacteria (3) New theory and technology of biological nitrogen and phosphorus removal. Prof. Su has published more than 50 SCI papers and authorized 11 invention patents. He has won several awards in the recent years including First Prize of Shaanxi Science and Technology Progress Award, Third Prize of Shaanxi Science and Technology Progress Award, First Prize of Science and Technology Award of Shaanxi Provincial Higher Education, and Second Prize of Science and Technology Award of Shaanxi Provincial Higher Education.

Dr. Jinwei Zhang is a Lecturer in Biomedical Sciences in the University of Exeter Medical School. His laboratory studies signalling pathways that associated with human diseases, for examples, neuropsychiatric disorders (WNK-SPAK-KCC2) and hypertension (CUL3/KLHL3-WNK-SPAK-NCC) and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules and CRISPR/Cas9 knock-in and knock-out technologies to aid discovery and validation of new potential drug targets. He has published more than 40 articles in journals including Nature Medicine, Nature Communications and Cell Metabolism etc.